Frédéric Revah
Vorstandsvorsitzender bei Genethon
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Stéphane Degove | M | - |
Atamyo Therapeutics SAS
 Atamyo Therapeutics SAS BiotechnologyHealth Technology Atamyo Therapeutics SAS is a clinical-stage biopharmaceutical company based in France. Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon, a spin-off of gene therapy pioneer Genethon. Atamyo's most advanced programs address different forms of limb-girdle muscular dystrophies (LGMD), with two clinical-stage programs targeting respectively LGMD-R9 and LGMD-R5. The name of the French company is derived from two words\: Celtic Atao which means "always" or "forever" and Myo which is the Greek root for muscle. Atamyo conveys the spirit of its commitment to improve the life of patients affected by neuromuscular diseases with life-long efficient treatments. Atamyo brings to patients with musculoskeletal diseases a new generation of gene therapies with enhanced safety and efficacy. The private company was founded in 2020 by Stéphane Degove and Isabelle Richard. Stéphane Degove has been the CEO since 2020. | 4 Jahre |
| Marie-Christine Ouillade | F | - |
Genethon
 Genethon BiotechnologyHealth Technology Genethon is a biotherapy research and development firm, which engages in the design, development, and production of gene therapy treatments for rare diseases. It specializes in neuromuscular diseases, immune system or blood disorders, eye disorders, and liver and nervous system diseases. The company was founded in 1990 and is headquartered in Evry, France. | - |
| Marc Bouillet | M | - |
Genethon
Genethon BiotechnologyHealth Technology Genethon is a biotherapy research and development firm, which engages in the design, development, and production of gene therapy treatments for rare diseases. It specializes in neuromuscular diseases, immune system or blood disorders, eye disorders, and liver and nervous system diseases. The company was founded in 1990 and is headquartered in Evry, France. | - |
| Alexandre Lemoalle | M | - |
Genethon
Genethon BiotechnologyHealth Technology Genethon is a biotherapy research and development firm, which engages in the design, development, and production of gene therapy treatments for rare diseases. It specializes in neuromuscular diseases, immune system or blood disorders, eye disorders, and liver and nervous system diseases. The company was founded in 1990 and is headquartered in Evry, France.
Atamyo Therapeutics SAS
Atamyo Therapeutics SAS BiotechnologyHealth Technology Atamyo Therapeutics SAS is a clinical-stage biopharmaceutical company based in France. Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon, a spin-off of gene therapy pioneer Genethon. Atamyo's most advanced programs address different forms of limb-girdle muscular dystrophies (LGMD), with two clinical-stage programs targeting respectively LGMD-R9 and LGMD-R5. The name of the French company is derived from two words\: Celtic Atao which means "always" or "forever" and Myo which is the Greek root for muscle. Atamyo conveys the spirit of its commitment to improve the life of patients affected by neuromuscular diseases with life-long efficient treatments. Atamyo brings to patients with musculoskeletal diseases a new generation of gene therapies with enhanced safety and efficacy. The private company was founded in 2020 by Stéphane Degove and Isabelle Richard. Stéphane Degove has been the CEO since 2020. | 9 Jahre |
| Isabelle Richard | F | - |
Atamyo Therapeutics SAS
Atamyo Therapeutics SAS BiotechnologyHealth Technology Atamyo Therapeutics SAS is a clinical-stage biopharmaceutical company based in France. Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon, a spin-off of gene therapy pioneer Genethon. Atamyo's most advanced programs address different forms of limb-girdle muscular dystrophies (LGMD), with two clinical-stage programs targeting respectively LGMD-R9 and LGMD-R5. The name of the French company is derived from two words\: Celtic Atao which means "always" or "forever" and Myo which is the Greek root for muscle. Atamyo conveys the spirit of its commitment to improve the life of patients affected by neuromuscular diseases with life-long efficient treatments. Atamyo brings to patients with musculoskeletal diseases a new generation of gene therapies with enhanced safety and efficacy. The private company was founded in 2020 by Stéphane Degove and Isabelle Richard. Stéphane Degove has been the CEO since 2020. | 4 Jahre |
| Claude Allary | M | 69 |
Genethon
Genethon BiotechnologyHealth Technology Genethon is a biotherapy research and development firm, which engages in the design, development, and production of gene therapy treatments for rare diseases. It specializes in neuromuscular diseases, immune system or blood disorders, eye disorders, and liver and nervous system diseases. The company was founded in 1990 and is headquartered in Evry, France. | - |
| Roger Hajjar | M | - |
Atamyo Therapeutics SAS
Atamyo Therapeutics SAS BiotechnologyHealth Technology Atamyo Therapeutics SAS is a clinical-stage biopharmaceutical company based in France. Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon, a spin-off of gene therapy pioneer Genethon. Atamyo's most advanced programs address different forms of limb-girdle muscular dystrophies (LGMD), with two clinical-stage programs targeting respectively LGMD-R9 and LGMD-R5. The name of the French company is derived from two words\: Celtic Atao which means "always" or "forever" and Myo which is the Greek root for muscle. Atamyo conveys the spirit of its commitment to improve the life of patients affected by neuromuscular diseases with life-long efficient treatments. Atamyo brings to patients with musculoskeletal diseases a new generation of gene therapies with enhanced safety and efficacy. The private company was founded in 2020 by Stéphane Degove and Isabelle Richard. Stéphane Degove has been the CEO since 2020. | 1 Jahre |
| Laurence Tiennot-Herment | F | - |
Genethon
Genethon BiotechnologyHealth Technology Genethon is a biotherapy research and development firm, which engages in the design, development, and production of gene therapy treatments for rare diseases. It specializes in neuromuscular diseases, immune system or blood disorders, eye disorders, and liver and nervous system diseases. The company was founded in 1990 and is headquartered in Evry, France. | 15 Jahre |
| Marie-Yvonne Landel-Meunier | F | 71 |
Genethon
Genethon BiotechnologyHealth Technology Genethon is a biotherapy research and development firm, which engages in the design, development, and production of gene therapy treatments for rare diseases. It specializes in neuromuscular diseases, immune system or blood disorders, eye disorders, and liver and nervous system diseases. The company was founded in 1990 and is headquartered in Evry, France. | - |
| Claude Le Pen | M | - |
Genethon
Genethon BiotechnologyHealth Technology Genethon is a biotherapy research and development firm, which engages in the design, development, and production of gene therapy treatments for rare diseases. It specializes in neuromuscular diseases, immune system or blood disorders, eye disorders, and liver and nervous system diseases. The company was founded in 1990 and is headquartered in Evry, France. | - |
| Jean-Pierre Lamorte | M | - |
Genethon
Genethon BiotechnologyHealth Technology Genethon is a biotherapy research and development firm, which engages in the design, development, and production of gene therapy treatments for rare diseases. It specializes in neuromuscular diseases, immune system or blood disorders, eye disorders, and liver and nervous system diseases. The company was founded in 1990 and is headquartered in Evry, France. | 17 Jahre |
| Nathalie Triclin-Conseil | F | - |
Genethon
Genethon BiotechnologyHealth Technology Genethon is a biotherapy research and development firm, which engages in the design, development, and production of gene therapy treatments for rare diseases. It specializes in neuromuscular diseases, immune system or blood disorders, eye disorders, and liver and nervous system diseases. The company was founded in 1990 and is headquartered in Evry, France. | - |
| Marie-Christine Belleville | F | - |
Genethon
Genethon BiotechnologyHealth Technology Genethon is a biotherapy research and development firm, which engages in the design, development, and production of gene therapy treatments for rare diseases. It specializes in neuromuscular diseases, immune system or blood disorders, eye disorders, and liver and nervous system diseases. The company was founded in 1990 and is headquartered in Evry, France. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Thierry Vernier | M | - | - | |
| Philippe Pierre Goupit | M | - | 20 Jahre | |
| Nicolas Papadopoulo | M | 61 |
Ecole Polytechnique
| 4 Jahre |
| Alexis Marincic | M | - |
Ecole Polytechnique
| 4 Jahre |
| François Langrand | M | - |
Ecole Polytechnique
| 4 Jahre |
| Haila Wang | M | - |
Ecole Polytechnique
| 4 Jahre |
| Guilles Corroy | M | 58 |
Université de Paris 5 René Descartes
| 1 Jahre |
| Pierre Rocque | M | - |
Ecole Polytechnique
| 4 Jahre |
| Serge Lafon | M | 62 |
Ecole Polytechnique
| 4 Jahre |
| Laurent Castaing | M | 64 |
Ecole Polytechnique
| 4 Jahre |
| Eric Dalbies | M | 56 |
Ecole Polytechnique
| 4 Jahre |
| Marc Bury | M | - |
Ecole Polytechnique
| 4 Jahre |
| Yann Le Garrec | M | - |
Ecole Polytechnique
| 3 Jahre |
| Samir Mohammed Tazi | M | 60 |
Ecole Polytechnique
| 4 Jahre |
| Françoise Clemes | F | 57 |
Université de Paris 5 René Descartes
| 1 Jahre |
| Thierry Podolak | M | 60 |
Ecole Polytechnique
| 4 Jahre |
| Imad Toumi | M | 60 |
Ecole Polytechnique
| 4 Jahre |
| Fabrice Henry | M | - |
Ecole Polytechnique
| 4 Jahre |
| Alain Herrera | M | 74 | 10 Jahre | |
| Frédéric Verger | M | 59 |
Ecole Polytechnique
| 4 Jahre |
| Eric Imbert | M | - |
Ecole Polytechnique
| 4 Jahre |
| Jim Robinson | M | - | 8 Jahre | |
| Christopher Hwang | M | 61 | 24 Jahre | |
| Carol Jean Noel Bléry | F | 61 | 24 Jahre | |
| Matthias Hebben | M | - |
Genethon
Genethon BiotechnologyHealth Technology Genethon is a biotherapy research and development firm, which engages in the design, development, and production of gene therapy treatments for rare diseases. It specializes in neuromuscular diseases, immune system or blood disorders, eye disorders, and liver and nervous system diseases. The company was founded in 1990 and is headquartered in Evry, France. | 6 Jahre |
| Valerie Salentey | M | - |
Genethon
Genethon BiotechnologyHealth Technology Genethon is a biotherapy research and development firm, which engages in the design, development, and production of gene therapy treatments for rare diseases. It specializes in neuromuscular diseases, immune system or blood disorders, eye disorders, and liver and nervous system diseases. The company was founded in 1990 and is headquartered in Evry, France. | 2 Jahre |
| Federico Mingozzi | M | 50 |
Genethon
Genethon BiotechnologyHealth Technology Genethon is a biotherapy research and development firm, which engages in the design, development, and production of gene therapy treatments for rare diseases. It specializes in neuromuscular diseases, immune system or blood disorders, eye disorders, and liver and nervous system diseases. The company was founded in 1990 and is headquartered in Evry, France. | 4 Jahre |
| Vincent Deperrois | M | 58 |
Ecole Polytechnique
| 4 Jahre |
| Abdelouafi Laftit | M | - |
Ecole Polytechnique
| 4 Jahre |
| Luc Vincent | M | 59 |
Ecole Polytechnique
| 4 Jahre |
| Emmanuel Dulac | M | 55 | 9 Jahre | |
| Fulvio Mavilio | M | - |
Genethon
Genethon BiotechnologyHealth Technology Genethon is a biotherapy research and development firm, which engages in the design, development, and production of gene therapy treatments for rare diseases. It specializes in neuromuscular diseases, immune system or blood disorders, eye disorders, and liver and nervous system diseases. The company was founded in 1990 and is headquartered in Evry, France. | 5 Jahre |
| Géraldine Honnet | M | - |
Genethon
Genethon BiotechnologyHealth Technology Genethon is a biotherapy research and development firm, which engages in the design, development, and production of gene therapy treatments for rare diseases. It specializes in neuromuscular diseases, immune system or blood disorders, eye disorders, and liver and nervous system diseases. The company was founded in 1990 and is headquartered in Evry, France. | 9 Jahre |
| Samantha Truex | F | - | 8 Jahre | |
| Gilles Reynaert | M | 65 |
Ecole Polytechnique
| 4 Jahre |
| Hugues de Saint Germain | M | 59 |
Ecole Polytechnique
| 4 Jahre |
| David L. Guy | M | 61 | 6 Jahre | |
| Olivier Andriès | M | 62 |
Ecole Polytechnique
| 4 Jahre |
| Henri Gagnaire | M | 61 |
Ecole Polytechnique
| 4 Jahre |
| Philippe Granger | M | - |
Ecole Polytechnique
| 4 Jahre |
| François Amzulesco | M | - |
Ecole Polytechnique
| 4 Jahre |
| Laurent Arthaud | M | 61 |
Ecole Polytechnique
| 4 Jahre |
| Philippe Charquet | M | 60 |
Ecole Polytechnique
| 4 Jahre |
| Emmanuel Roche | M | - |
Ecole Polytechnique
| 4 Jahre |
| Vincent Marcel | M | - |
Ecole Polytechnique
| 3 Jahre |
| Tidjane Thiam | M | 61 |
Ecole Polytechnique
| 4 Jahre |
| Henri Poupart-Lafarge | M | 55 |
Ecole Polytechnique
| 4 Jahre |
| Emmanuel Audousset | M | 64 |
Université de Paris 5 René Descartes
| 1 Jahre |
| Eric Bantégnie | M | 60 |
Ecole Polytechnique
| 4 Jahre |
| Jacques Veyrat | M | 61 |
Ecole Polytechnique
| 4 Jahre |
| Xavier Flinois | M | 61 |
Ecole Polytechnique
| 1 Jahre |
| Joseph Haddad | M | 66 |
Ecole Polytechnique
| 3 Jahre |
| Philippe Demigné | M | 63 |
Ecole Polytechnique
| 4 Jahre |
| Alice S. Bexon | M | 54 | 3 Jahre | |
| Vladimir Šelebaj-Sellier | M | 58 |
Université de Paris 5 René Descartes
| 4 Jahre |
| Henri Piganeau | M | - |
Ecole Polytechnique
| 3 Jahre |
| Pascal Faure | M | 61 |
Ecole Polytechnique
| 4 Jahre |
| Bassim Jaï Hokimi | M | - |
Ecole Polytechnique
| 2 Jahre |
| Frédéric J. M. Schneider-Maunoury | M | 63 |
Ecole Polytechnique
| 4 Jahre |
| Eric Denoyer | M | 60 |
Ecole Polytechnique
| 4 Jahre |
| Elsa Borghi | M | - |
Université de Paris 5 René Descartes
| 3 Jahre |
| Pascale Sourisse | F | 61 |
Ecole Polytechnique
| 4 Jahre |
| Frank Stonebanks | M | - | 5 Jahre | |
| Nicolas Schimel | M | 59 |
Ecole Polytechnique
| 4 Jahre |
| Karen Linehan | F | 65 | 25 Jahre | |
| Mehdi Gasmi | M | 57 |
Genethon
Genethon BiotechnologyHealth Technology Genethon is a biotherapy research and development firm, which engages in the design, development, and production of gene therapy treatments for rare diseases. It specializes in neuromuscular diseases, immune system or blood disorders, eye disorders, and liver and nervous system diseases. The company was founded in 1990 and is headquartered in Evry, France. | 2 Jahre |
| Didier Valet | M | 56 |
Ecole Polytechnique
| 4 Jahre |
| Loïc Lietar | M | 62 |
Ecole Polytechnique
| 4 Jahre |
| Bruno Vasselle | M | - |
Ecole Polytechnique
| 4 Jahre |
| Jeans-Marc Verdiell | M | - |
Ecole Polytechnique
| 1 Jahre |
| Geneviéve B. Berger | M | 69 |
Université de Paris 5 René Descartes
| 3 Jahre |
| Paul Leondaridis | M | - |
Ecole Polytechnique
| 2 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Frankreich | 85 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Frédéric Revah
- Persönliches Netzwerk
